Evidence map›Paper›PMID 28898698›Full record

ArticleCancer cell2017

Enhancing CD8

Ying Zhang, Raj Kurupati, Ling Liu, Xiang Yang Zhou, Gao Zhang, Abeer Hudaihed, Flavia Filisio, Wynetta Giles-Davis, Xiaowei Xu, Giorgos C Karakousis and 10 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 418 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
418citing papers in PubMed, 1 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

418 citing papers in PubMed, 1 synthesis or guideline pooled it, 590 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. CD8MedComm · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

358 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Ying ZhangGene Therapy and Vaccines Program, University of Pennsylvania (U of PA), Philadelphia, PA 19104, USA; The Wistar Institute, Philadelphia, PA 19104, USA.
Raj KurupatiThe Wistar Institute, Philadelphia, PA 19104, USA.
Ling LiuLewis-Sigler Institute for Integrative Genomics & Department of Chemistry, Princeton University, Princeton, NJ 08540, USA.
Xiang Yang ZhouThe Wistar Institute, Philadelphia, PA 19104, USA.
Gao ZhangThe Wistar Institute, Philadelphia, PA 19104, USA.
Abeer HudaihedBiology Program, Temple University, Philadelphia, PA 19122, USA.
Flavia FilisioBiology Program, Temple University, Philadelphia, PA 19122, USA.
Wynetta Giles-DavisThe Wistar Institute, Philadelphia, PA 19104, USA.
Xiaowei XuDepartment of Pathology and Laboratory Medicine, U of PA, Philadelphia, PA 19104, USA.
Giorgos C KarakousisDepartment of Surgery, Hospital of U of PA, Philadelphia, PA 19104, USA.
Lynn M SchuchterDepartment of Medicine, U of PA, Philadelphia, PA 19104, USA.
Wei XuDepartment of Medicine, U of PA, Philadelphia, PA 19104, USA.
Ravi AmaravadiDepartment of Medicine, U of PA, Philadelphia, PA 19104, USA.
Min XiaoThe Wistar Institute, Philadelphia, PA 19104, USA.
Norah SadekThe Wistar Institute, Philadelphia, PA 19104, USA.
Clemens KreplerThe Wistar Institute, Philadelphia, PA 19104, USA.
Meenhard HerlynThe Wistar Institute, Philadelphia, PA 19104, USA.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Joshua D RabinowitzLewis-Sigler Institute for Integrative Genomics & Department of Chemistry, Princeton University, Princeton, NJ 08540, USA.
Hildegund C J ErtlThe Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: ertl@wistar.org.
The Wistar Institute · USPrinceton University · USTemple University · USDana-Farber Cancer Institute · USUniversity of Pennsylvania · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
Purchase a Beckman Coulter MoFlo Astrios Flow CytometerS10OD017998 · OD · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2014 to 2014
$595k
NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA174523NIH HHS S10 OD017998
6 · The paper itself

Abstract

How tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic constrains within the tumor microenvironment (TME) and to what degree this affects their ability to combat tumor progression remain poorly understood. Using mouse melanoma models, we report that CD8

Indexed as

ImmunotherapyAnimalsAntigens, CDCD8-Positive T-LymphocytesCell HypoxiaDisease ProgressionFatty AcidsFemaleGene Knockdown TechniquesGlucoseHumansHypoxia-Inducible Factor 1, alpha SubunitLymphocyte ActivationLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMelanomaAntigens, CDFatty AcidsGlucoseHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitLymphocyte Activation Gene 3 ProteinOxygenPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD8(+) T cellsco-inhibitorsfatty acid catabolismfenofibrateHIF-1αhypoglycemiahypoxiamelanomaTILstumor microenvironment

Identifiers

PMID28898698
PMCPMC5751418
OpenAlexW2755181857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.